The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient ...

With sales of Immunocore’s melanoma medicine steadily ticking up and an expanded label likely down the line, CEO Bahija ...

On this episode of "The Top Line," Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the clinical trial failures that stood out in 2025 and what they suggest about the ...

For millions of Americans with essential tremor, simple tasks like writing a note, putting on makeup or plugging in an appliance can be difficult. | For millions of Americans with essential tremor, ...

In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...

One month after Integra LifeSciences recalled its wound and burn devices amid safety concerns, the medtech company is cutting ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Sanofi is replacing CEO Paul Hudson with Merck KGaA leader Belén ...

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

Ultragenyx Pharmaceutical's employees were already braced for changes as the biopharma considered how to rebound from a pair ...

Elsewhere in the migraine prevention field, Lundbeck markets the infused drug Vyepti in the crowded CGRP inhibitor space. The ...

After a preliminary look at the numbers, the company says revenues in its fiscal 2023 and 2024 years "may have been ...